The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...